AquilaBioscience is a pioneer in bringing two critical areas of expertise to the fight against chronic and infectious diseases, cell stress and glycoscience. Aquila Bioscience has a strong focus on the use of polysaccharides for both preventing and treatment of disease. The combined expertise of cell biology and glycobiology at Aquila Bioscience allows our team to investigate the effects of different polysaccharides on a range of disease models.

Some major areas of interest at Aquila are:

  • Infectious diseases
  • Viral infections
  • Bacterial infections
  • Auto-immune diseases
  • Gut health

Aquila Bioscience is a spin-out company from the National University of Ireland Galway founded in August 2012. AquilaBioscience is developing innovative applications of glycoscience for health and diseases and for societal security to open up new niche opportunities for the company and the region. Aquila Bioscience has been funded by the EU under FP7, H2020 programmes and with funding from the European Defence Agency.”

Aquila Bioscience was founded by Professor Lokesh Joshi with a mission to develop nature inspired yet scientifically advanced technologies to enhance health and save lives.